← Back to home

J&J Strikes $2.2 Billion Deal for Eye-Disease Biotech Ollin

Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources

Brief

Johnson & Johnson said Nov. 16 it will buy Ollin Biosciences for $2.2 billion upfront, with up to about…

Keep reading with NewsPlain Premium

Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.

5 confirmed facts and 3 sources behind this story.

About this story

We haven’t published a correction to this story.

How NewsPlain works
← Back to home